DK167849B1 - Oliefri adjuvansblanding samt vaccine indeholdende denne - Google Patents

Oliefri adjuvansblanding samt vaccine indeholdende denne Download PDF

Info

Publication number: DK167849B1
Authority: DK; Denmark
Prior art keywords: oil; adjuvant; pluronic; mixture; carbopol
Prior art date: 1987-03-17

Application number

DK141488A

Other languages

Danish (da)

English (en)

Other versions

DK141488D0 (da

DK141488A (da

Inventor

Eric Onno Rijke

Original Assignee

Akzo Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-17

Filing date

1988-03-15

Publication date

1993-12-27

1988-03-15 Application filed by Akzo Nv filed Critical Akzo Nv

1988-03-15 Publication of DK141488D0 publication Critical patent/DK141488D0/da

1988-09-18 Publication of DK141488A publication Critical patent/DK141488A/da

1993-12-27 Application granted granted Critical

1993-12-27 Publication of DK167849B1 publication Critical patent/DK167849B1/da

Links

239000000203 mixture Substances 0.000 title claims description 17
229960005486 vaccine Drugs 0.000 title claims description 17
230000000570 adjustive effect Effects 0.000 title 1
239000002671 adjuvant Substances 0.000 claims description 27
229920002125 Sokalan® Polymers 0.000 claims description 26
-1 polyoxypropylene Polymers 0.000 claims description 22
244000052769 pathogen Species 0.000 claims description 16
229920001983 poloxamer Polymers 0.000 claims description 14
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
229920001451 polypropylene glycol Polymers 0.000 claims description 10
230000002163 immunogen Effects 0.000 claims description 9
239000000463 material Substances 0.000 claims description 9
230000001717 pathogenic effect Effects 0.000 claims description 8
238000002255 vaccination Methods 0.000 claims description 7
229920005862 polyol Polymers 0.000 claims description 6
150000003077 polyols Chemical class 0.000 claims description 6
238000002965 ELISA Methods 0.000 claims description 5
239000000427 antigen Substances 0.000 claims description 5
102000036639 antigens Human genes 0.000 claims description 5
108091007433 antigens Proteins 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
244000037640 animal pathogen Species 0.000 claims 2
241000588724 Escherichia coli Species 0.000 claims 1
229960001631 carbomer Drugs 0.000 claims 1
244000144977 poultry Species 0.000 claims 1
229920000642 polymer Polymers 0.000 description 10
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 9
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
241000700605 Viruses Species 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
241000282887 Suidae Species 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
230000010530 Virus Neutralization Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000000694 effects Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229920002359 Tetronic® Polymers 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
239000002502 liposome Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000006072 paste Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK141488A 1987-03-17 1988-03-15 Oliefri adjuvansblanding samt vaccine indeholdende denne DK167849B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8700629		1987-03-17
NL8700629		1987-03-17

Publications (3)

Publication Number	Publication Date
DK141488D0 DK141488D0 (da)	1988-03-15
DK141488A DK141488A (da)	1988-09-18
DK167849B1 true DK167849B1 (da)	1993-12-27

Family

ID=19849718

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK141488A DK167849B1 (da)	1987-03-17	1988-03-15	Oliefri adjuvansblanding samt vaccine indeholdende denne

Country Status (9)

Country	Link
US (1)	US5026543A (2)
EP (1)	EP0283085B1 (2)
JP (1)	JP2562827B2 (2)
DE (1)	DE3875762T2 (2)
DK (1)	DK167849B1 (2)
ES (1)	ES2052685T3 (2)
GR (1)	GR3007039T3 (2)
HU (1)	HU202119B (2)
ZA (1)	ZA881694B (2)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL105325A (en) *	1992-04-16	1996-11-14	Minnesota Mining & Mfg	Immunogen/vaccine adjuvant composition
EP0688205A1 (en) *	1993-03-11	1995-12-27	Secretech, Inc.	Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
US5961970A (en) *	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en) *	1993-10-29	1995-05-04	Pharmos Corp.	Submicron emulsions as vaccine adjuvants
GB9417742D0 (en) *	1994-09-03	1994-10-19	Univ Nottingham	Macrophage stimulating composition
BE1008977A5 (fr) *	1994-12-27	1996-10-01	Solvay	Adjuvants pour vaccins.
US5891393A (en) *	1996-04-09	1999-04-06	The University Of North Carolina At Chapel Hill	Method for the microbial decontamination of blood platelets
GB9622159D0 (en) *	1996-10-24	1996-12-18	Solvay Sociutu Anonyme	Polyanionic polymers as adjuvants for mucosal immunization
US6416779B1 (en)	1997-06-11	2002-07-09	Umd, Inc.	Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6572874B1 (en)	1998-05-15	2003-06-03	Umd, Inc.	Vaginal delivery of bisphosphonates
US6197327B1 (en) *	1997-06-11	2001-03-06	Umd, Inc.	Device and method for treatment of dysmenorrhea
FR2775601B1 (fr) *	1998-03-03	2001-09-21	Merial Sas	Vaccins vivants recombines et adjuves
FR2776928B1 (fr)	1998-04-03	2000-06-23	Merial Sas	Vaccins adn adjuves
NZ514323A (en) *	1999-03-24	2003-03-28	Secr Defence	A immunostimulant containing an acitive agent and an adjuvant which increases the effect of the active agent
US6943152B1 (en) *	1999-06-10	2005-09-13	Merial	DNA vaccine-PCV
MY129765A (en)	2000-12-19	2007-04-30	Wyeth Corp	Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en)	2000-12-19	2006-03-28	Wyeth	Mycoplasma hyopneumoniae bacterin vaccine
US6676958B2 (en)	2001-06-19	2004-01-13	Advanced Bioadjuvants, Llc	Adjuvant composition for mucosal and injection delivered vaccines
ES2391770T3 (es)	2003-01-21	2012-11-29	Novartis Vaccines And Diagnostics, Inc.	Uso de compuestos de triptantrina para la potenciación inmune
US7893096B2 (en)	2003-03-28	2011-02-22	Novartis Vaccines And Diagnostics, Inc.	Use of small molecule compounds for immunopotentiation
JP2008504292A (ja)	2004-06-24	2008-02-14	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	免疫増強用の化合物
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8097245B2 (en)	2005-12-28	2012-01-17	Advanced Bionutrition Corporation	Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
DK3766518T3 (da)	2005-12-29	2026-04-13	Boehringer Ingelheim Animal Health Usa Inc	Immunogen pcv2-sammensætning til mindskelse af kliniske symptomer hos grise
EP3868400A1 (en)	2005-12-29	2021-08-25	Boehringer Ingelheim Animal Health USA Inc.	Multivalent pcv2 immunogenic compositions and methods of producing such compositions
WO2007109810A2 (en) *	2006-03-23	2007-09-27	Novartis Ag	Methods for the preparation of imidazole-containing compounds
CA2646891A1 (en) *	2006-03-23	2007-09-27	Novartis Ag	Immunopotentiating compounds
CA2646539A1 (en)	2006-03-23	2007-09-27	Novartis Ag	Imidazoquinoxaline compounds as immunomodulators
EP2859900A1 (en)	2006-12-11	2015-04-15	Boehringer Ingelheim Vetmedica, Inc.	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
US20080292663A1 (en) *	2007-05-22	2008-11-27	Gerber Jay D	Adjuvant compositions and methods for delivering vaccines
KR20100113582A (ko)	2008-01-23	2010-10-21	베링거잉겔하임베트메디카인코퍼레이티드	Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
ES2467108T3 (es)	2008-12-09	2014-06-11	Gilead Sciences, Inc.	Moduladores de receptores tipo toll
ES2588183T3 (es) *	2009-03-31	2016-10-31	Japan As Represented By Director-General Of National Institute Of Infectious Diseases	Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
WO2010138522A2 (en)	2009-05-26	2010-12-02	Advanced Bionutrition Corporation	Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en)	2010-01-28	2016-11-29	Advanced Bionutrition Corporation	Stabilizing composition for biological materials
US8834951B2 (en)	2010-01-28	2014-09-16	Advanced Bionutrition Corporation	Dry glassy composition comprising a bioactive material
CA2866170A1 (en)	2012-03-12	2013-09-19	Advanced Bioadjuvants, Llc	Adjuvant and vaccine compositions
US9120859B2 (en)	2012-04-04	2015-09-01	Zoetis Services Llc	Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
MX373884B (es)	2013-10-02	2020-03-26	Boehringer Ingelheim Animal Health Usa Inc	Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
WO2016001907A1 (en)	2014-07-02	2016-01-07	Prendergast Patrick T	Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US12558395B2 (en)	2015-07-29	2026-02-24	Advanced Bionutrition Corp.	Stable dry probiotic compositions for special dietary uses
JP6889699B2 (ja)	2015-07-29	2021-06-18	アドバンスドバイオニュートリションコープ．	特定栄養用途のための安定乾燥プロバイオティクス組成物
TW202015725A (zh)	2018-06-04	2020-05-01	美商亞博創新醫藥有限公司	Tlr7 肽結合物
KR20210027381A (ko)	2018-07-02	2021-03-10	아유비스 리서치, 인코포레이티드	신규 면역조절 소분자

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3178350A (en) *	1961-05-15	1965-04-13	Cutler Lab Inc	Biologic antigens adjuvanted with a colloidally water-soluble polymer of acrylic acidcrosslinked with polyallyl sucrose or polyallyl pentaerythritol
US3919411A (en) *	1972-01-31	1975-11-11	Bayvet Corp	Injectable adjuvant and compositions including such adjuvant
US3869546A (en) *	1972-12-22	1975-03-04	Cutter Lab	Adjuvant compositions and medicinal mixtures comprising them
DE3308458A1 (de) *	1983-03-10	1984-09-13	Behringwerke Ag, 3550 Marburg	Verfahren zur adjuvierung von vaccinen
US4567042A (en) *	1983-06-15	1986-01-28	American Home Products Corporation	Inactivated canine coronavirus vaccine
US4567043A (en) *	1983-06-15	1986-01-28	American Home Products Corporation (Del.)	Canine corona virus vaccine
US4606918A (en) *	1983-08-22	1986-08-19	Syntex (U.S.A.) Inc.	Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) *	1983-08-22	1988-09-20	Syntex (U.S.A.) Inc.	Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants

1988
- 1988-03-09 EP EP88200443A patent/EP0283085B1/en not_active Expired - Lifetime
- 1988-03-09 ZA ZA881694A patent/ZA881694B/xx unknown
- 1988-03-09 DE DE8888200443T patent/DE3875762T2/de not_active Expired - Fee Related
- 1988-03-09 ES ES88200443T patent/ES2052685T3/es not_active Expired - Lifetime
- 1988-03-15 DK DK141488A patent/DK167849B1/da not_active IP Right Cessation
- 1988-03-16 HU HU881255A patent/HU202119B/hu not_active IP Right Cessation
- 1988-03-16 JP JP63063073A patent/JP2562827B2/ja not_active Expired - Fee Related
1989
- 1989-09-27 US US07/414,648 patent/US5026543A/en not_active Expired - Lifetime
1993
- 1993-02-11 GR GR930400270T patent/GR3007039T3/el unknown

Also Published As

Publication number	Publication date
ZA881694B (en)	1988-09-06
HUT47224A (en)	1989-02-28
JP2562827B2 (ja)	1996-12-11
DK141488D0 (da)	1988-03-15
DE3875762D1 (de)	1992-12-17
DE3875762T2 (de)	1993-05-13
ES2052685T3 (es)	1994-07-16
DK141488A (da)	1988-09-18
EP0283085B1 (en)	1992-11-11
JPS63253032A (ja)	1988-10-20
HU202119B (en)	1991-02-28
US5026543A (en)	1991-06-25
EP0283085A1 (en)	1988-09-21
GR3007039T3 (2)	1993-07-30

Legal Events

Date	Code	Title	Description
1993-12-27	B1	Patent granted (law 1993)
1999-10-25	PBP	Patent lapsed

Publication	Publication Date	Title
DK167849B1 (da)	1993-12-27	Oliefri adjuvansblanding samt vaccine indeholdende denne
US5565209A (en)	1996-10-15	Adjuvant mixture
Rankin et al.	2002	CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D
NZ553165A (en)	2008-09-26	Vaccine composition comprising West Nile viral DNA an oil adjuvant such as squalane and optionally wetting and dispersing agents
US4117112A (en)	1978-09-26	Vaccine for prevention of feline leukemia
Fratzke et al.	2022	Immunogenicity and reactogenicity in Q fever vaccine development
US5914113A (en)	1999-06-22	Inactivated vaccines
Shebl et al.	2021	Staphylococcus aureus derived hyaluronic acid and bacillus Calmette-Guérin purified proteins as immune enhancers to rabies vaccine and related immuno-histopathological alterations
CA3106341A1 (en)	2020-01-16	New vaccines against avian reoviruses
Cutlip et al.	1987	Failure of experimental vaccines to protect against infection with ovine progressive pneumonia (maedi-visna) virus
KR20200053644A (ko)	2020-05-18	보강제 제형 및 방법
JP5470052B2 (ja)	2014-04-16	動物の感染症を治療または予防するための免疫原組成物
Fatunmbi et al.	1992	Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant
Rehmani et al.	1995	The influence of adjuvants on oral vaccination of chickens against Newcastle disease
CN110507819B (zh)	2021-02-19	青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
Morein	1987	Potentiation of the immune response by immunization with antigens in defined multimeric physical forms
EP3691679A2 (en)	2020-08-12	Feline vaccines conferring early protection
Johnson et al.	1986	Intracerebral infection of mice with ovine strains of Chlamydia psittaci: an animal screening test for the assay of vaccines
Mahboob et al.	1999	Preparation and evaluation of newcastle disease oil emulsion vaccine at hydrophile lipophile balance 7.0 using mukteswar strain
HASAN et al.	2017	The immune response induced by E. coli in chickens and available vaccines.
Mutwiri et al.	2009	5 potential of polyphosphazenes in modulating vaccine-induced immune responses
CA2052459A1 (en)	1992-04-02	Vaccinal association against infective pathogenic agents
JP2026071309A (ja)	2026-04-28	経口呼吸器ワクチン
FAYED et al.	2000	PREPRATION OF A SPECIFIC INACTIVATED PESTE DES PETITS RUMINATS VACCINE
Fatunmbi et al.	1992	Efficacy of avridine and liposomes as adjuvants for avian influenza virus antigens in turkeys